BiotechTube
Kidswell Bio

Kidswell Bio

Fukuoka, Japan· Est.

Japanese biotech developing SHED-based cell therapies for pediatric neurological disorders and operating a dual business model with biosimilars.

kidswellbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

Japanese biotech developing SHED-based cell therapies for pediatric neurological disorders and operating a dual business model with biosimilars.

OncologyFibrosisNeurologyPediatrics

Technology Platform

Proprietary S-Quatre® platform for isolating, culturing, and manufacturing GMP-grade master cell banks of Stem cells from Human Exfoliated Deciduous teeth (SHED), which exhibit enhanced proliferative capacity and neurotrophic factor production.

Opportunities

Large unmet medical need in pediatric cerebral palsy and other neurological disorders; potential to leverage the S-Quatre® platform for multiple allogeneic cell therapy indications and out-licensing to other developers.

Risk Factors

Clinical risk associated with novel SHED-based cell therapy; regulatory hurdles for cell therapy approval; competition from other regenerative medicine approaches and established rehabilitation methods.

Competitive Landscape

Competes with other MSC therapy developers (e.g., Mesoblast) and gene therapy companies in neurology. Differentiation lies in the unique SHED source, proprietary manufacturing, and specific pediatric focus.

More companies in Japan →